Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.

J Naidoo; SJ Antonia; YL Wu; BC Cho; P Thiyagarajah; H Mann; MD Newton; C Faivre-Finn

Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.

J Naidoo, SJ Antonia, YL Wu, BC Cho, P Thiyagarajah, H Mann, MD Newton, C Faivre-Finn

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

Cite this

@article{8c23d949f0cf4e0faeb054fa94f6e864,

title = "Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.",

author = "J Naidoo and SJ Antonia and YL Wu and BC Cho and P Thiyagarajah and H Mann and MD Newton and C Faivre-Finn",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

TY - JOUR

T1 - Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC

T2 - A post hoc subgroup analysis from PACIFIC.

AU - Naidoo, J

AU - Antonia, SJ

AU - Wu, YL

AU - Cho, BC

AU - Thiyagarajah, P

AU - Mann, H

AU - Newton, MD

AU - Faivre-Finn, C

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680302143&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.

Other files and links

Cite this